Table 1.
Demographic and baseline clinical characteristics of patients with resectable pancreatic adenocarcinoma (n=460)
| Characteristics | All patients (n=460) |
Preoperative serum CA19-9a
|
Preoperative serum CEAb
|
||||
|---|---|---|---|---|---|---|---|
| <37 U/mL (n=153) |
≥37 U/mL (n=301) |
P-value | <5 μg/mL (n=304) |
≥5 μg/mL (n=104) |
P-value | ||
| Age, median (q1–q3, years) | 62 (56–68) | 60 (54–66) | 62 (57–69) | 0.0045* | 61 (56–67) | 65 (57–72) | 0.01* |
| Diabetes, N (%) | 0.23 | 0.58 | |||||
| Yes | 102 (24.2) | 29 (20.7) | 72 (26.0) | 70 (23.3) | 27 (26.0) | ||
| No | 322 (75.8) | 111 (79.3) | 205 (74.0) | 232 (76.7) | 77 (74.0) | ||
| Tumor location, N (%) | 0.13 | 0.39 | |||||
| Head of pancreas | 143 (31.1) | 54 (35.5) | 86 (28.6) | 97 (31.9) | 38 (36.5) | ||
| Body or tail of pancreas | 317 (68.9) | 98 (64.5) | 215 (71.4) | 207 (68.1) | 66 (63.5) | ||
| Tumor stage, N (%) | <0.0001* | 0.05 | |||||
| T1/T2 | 115 (25.9) | 56 (38.9) | 58 (19.9) | 83 (28.3) | 18 (18.4) | ||
| T3/T4 | 328 (74.1) | 88 (61.1) | 234 (80.1) | 210 (71.7) | 80 (81.6) | ||
| Lymph node stage, N (%) | 0.08 | 0.04* | |||||
| N1 | 206 (55.2) | 59 (38.8) | 143 (47.5) | 120 (39.5) | 53 (51.0) | ||
| N0 | 254 (44.8) | 93 (61.2) | 158 (52.5) | 184 (60.5) | 51 (49.0) | ||
| AJCC stage, N (%) | <0.0001* | 0.03* | |||||
| IA/IB | 68 (15.4) | 38 (26.4) | 30 (10.3) | 54 (18.4) | 9 (9.2) | ||
| IIA/IIB | 286 (64.6) | 89 (61.8) | 190 (65.1) | 186 (63.5) | 62 (63.3) | ||
| III | 89 (22.1) | 17 (11.8) | 72 (24.7) | 53 (18.1) | 27 (27.5) | ||
| Chemotherapy, N (%) | 360 (78.3) | 119 (78.3) | 234 (77.7) | 0.89 | 226 (74.34) | 84 (80.1) | 0.19 |
Notes:
a
Seven missing values,
b
52 missing values.
*
Statiscally significant.
Abbreviations: AJCC, American Joint Committee on Cancer; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.